Bradford A. Zakes

Mr. Zakes has served as the company’s President and Chief Executive Officer since the inception of Cerevast Therapeutics in 2009. Previously, he served as President and CEO of ImaRx Therapeutics, Inc. a publicly-traded biopharmaceutical company focused on the development of microsphere technology and biotherapeutics. Mr. Zakes has spent 30+ years in various segments of the pharmaceutical, biotechnology, and med-tech industries. Following his career as a commissioned officer in the United States Army, Mr. Zakes held positions at Hazleton Laboratories, Glaxo (currently Glaxo Smithkline), and ICOS Corporation. While at Glaxo, Mr. Zakes played an active role in the clinical development of Zantac and Serevent. Mr. Zakes holds a BS degree in Biology from Oregon State University, an MS degree in Toxicology from the American University, and an MBA from Duke University’s Fuqua School of Business. Additionally, Mr. Zakes serves on the Board of Directors and Executive Committee for the Biotechnology Industry Organization (BIO) as well as the Emerging Company Section Governing Body and the Standing Committees on International Affairs and Finance and Investment for BIO.